BACKGROUND Considering that depressive and anxiety symptoms are common in schizophrenia, this study investigated whether the severity of a psychotic episode in an acute phase schizophrenia cohort is predictive of concurrent depressive and anxiety features. METHOD Fifty one recently hospitalised patients suffering from acute phase schizophrenia participated prospectively in a cross-sectional s...

INTRODUCTION The aim of our study was to evaluate the relationship between neutrophil/lymphocyte ratio (NLR) and total antioxidant status (TAS), total oxidative status (TOS), oxidative stress index (OSI), paraoxonase, and total thiol (T.thl) in schizophrenic patients compared to healthy control group and investigate the relationship between these parameters and psychopathological symptoms. ME...

BACKGROUND Self-report instruments for the assessment of depressive symptoms in patients with psychotic disorders are scarce. The Quick Inventory of Depressive Symptoms (QIDS-SR16) may be a useful self-report instrument, but has received little attention in this field. This paper aimed to test the psychometric properties of the QIDS-SR16 questionnaire in patients with a psychotic disorder. ME...

OBJECTIVE Blonanserin is a novel atypical antipsychotic drug that has efficacy equal to risperidone. We investigated the effects of aripiprazole and blonanserin on clinical symptoms and plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol in the switching strategy of schizophrenia. METHODS Twenty two Japanese patients with schizophrenia were enrolled into this open stu...

OBJECTIVE This study examined the risk factors for decreased bone mineral density (BMD) in postmenopausal women with schizophrenia. METHODS Cluster sampling method was adopted in this large-sample, cross-sectional study. A total of 219 postmenopausal female inpatients with schizophrenia were selected and interviewed in Beijing. The average age of the patients was 60.4±7.0 years. Clinical asse...

BACKGROUND Long-acting injectable antipsychotics are treatment options for acute and long-term treatment of patients with schizophrenia. In a previously published 12-week randomized, double-blind, placebo-controlled clinical trial of patients with schizophrenia experiencing an acute psychotic episode, aripiprazole once-monthly 400 mg (AOM 400) produced significantly greater improvement than pla...

Sixty six patients of either sex with a diagnosis of schizophrenia as per DSM III-R criteria were enrolled in an open, non-comparative study. They were treated with loxapine over a duration of 6 weeks. The assessment of the patients was carried out using the Positive and Negative Syndrome Scale (PANSS) and Clinical global Impression (CGI) Scale. The side effects were noted on the Extrapyramidal...

Background Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955). Aims To examine the five individ...

OBJECTIVE The study was designed to evaluate the short-term efficacy and safety of lurasidone in the treatment of acute schizophrenia. METHOD Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly assigned to 6 weeks of double-blind treatment with 40 mg of lurasidone, 120 mg of lurasidone, 15 mg of olanzapine (inc...

BACKGROUND Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia. METHODS An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion ...